To a certain extent, during the risk assessment processes, the government has tried to build in these safety factors to take into account vulnerable populations and people within these windows of vulnerability. The trouble, I think, is that for endocrine-disrupting substances, the whole structure of section 64 is not conducive to being able to do that. Really, within section 64, you need less emphasis on exposure. We can say that we, in the act, generally want to consider vulnerable populations, but unless we actually change the operative provisions in the act that are not now serving those populations, we won't actually have that effect.
On June 9th, 2016. See this statement in context.